| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_86d39e37af3a937b835f2fbe72541e1e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2207-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16632
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-0331 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-768
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-763
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7084
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7088 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-763
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7084
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2020-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21e0ebc5ad5c77f0520ce93a7f27e523
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_172d0daeb7d9f1cfb16f6cde8d090c3e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9035de063147a1ed6d83aba1632b3415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3f22f5d1242f6d627cc604c2677a9936 |
| publicationDate |
2022-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2022273739-A1 |
| titleOfInvention |
Combination drug for treating malignant tumor, pharmaceutical composition for treating malignant tumor, and pharmaceutical composition for malignant tumor treatment |
| abstract |
Provided are a combination drug for treating a malignant tumor, a pharmaceutical composition for treating a malignant tumor, and a pharmaceutical composition for malignant tumor treatment that have an exceptional antitumor effect. A malignant tumor can be treated by a combination drug containing a first medicine that includes an oncolytic virus belonging to the herpes simplex viruses type 1 as an active ingredient, and a second medicine that includes an interferon gene stimulating factor agonist as an active ingredient. |
| priorityDate |
2019-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |